Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Sage Therapeutics announced a live webcast on November 5, 2020, at 8:30 a.m. ET to present its third quarter 2020 financial results and discuss recent business updates. The event will be accessible via the investor page on Sage's website. A replay of the webcast will be available shortly after the event and will remain archived for 30 days. Sage Therapeutics focuses on developing innovative therapies for brain disorders, aiming to enhance brain health through its depression and neurology programs.
- Sage Therapeutics is committed to transforming treatments for brain disorders.
- The company is actively developing novel therapies targeting depression and neurology.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to announce third quarter 2020 financial results and discuss recent business updates.
The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
